OCUL — Ocular Therapeutix Share Price
0.000.00%
Last trade - 00:00- $1.53bn
- $1.14bn
- $58.44m
- 54
- 12
- 86
- 49
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 4.06 | ||
| Price to Tang. Book | 4.06 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 25.11 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -26.32% | ||
| Return on Equity | -72.67% | ||
| Operating Margin | -209.88% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 4.23 | 17.4 | 43.52 | 51.49 | 58.44 | 66.18 | 74.95 | 96.6% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Ocular Therapeutix, Inc. is a biopharmaceutical company. The Company is engaged in the development and commercialization of therapies for wet age-related macular degeneration (wet AMD), diabetic retinopathy, and other diseases and conditions of the eye. Its first commercial drug product, DEXTENZA, is for the treatment of ocular inflammation and pain following ophthalmic surgery and ocular itching associated with allergic conjunctivitis. It is also developing two other clinical-stage assets, OTX-DED (dexamethasone intracanalicular insert) for the short-term treatment of the signs and symptoms of dry eye disease, and OTX-CSI (cyclosporine intracanalicular insert) for the chronic treatment of dry eye disease. It is conducting a pivotal Phase III clinical trial to evaluate AXPAXLI for the treatment of wet AMD. Its clinical portfolio also includes PAXTRAVA, which is in Phase III clinical development for the treatment of primary open-angle glaucoma (OAG) or ocular hypertension (OHT).
Directors
- Charles Warden NEC (52)
- Antony Mattessich PRE (54)
- Donald Notman CFO (61)
- Michael Goldstein CEX (54)
- Philip Strassburger GCN (61)
- Merilee Raines DRC (65)
- Jeffrey Heier IND (60)
- Seung Suh Hong IND (63)
- Richard Lindstrom IND (73)
- Bruce Peacock IND (69)
- Leslie Williams IND (61)
- Last Annual
- December 31st, 2023
- Last Interim
- June 30th, 2024
- Incorporated
- September 12th, 2006
- Public Since
- July 25th, 2014
- No. of Shareholders
- 29
- No. of Employees
- 267
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- NASDAQ Global Market
- Shares in Issue
- 155,921,685
- Address
- 15 Crosby Drive, BEDFORD, 01730
- Web
- https://www.ocutx.com/
- Phone
- +1 7813574000
- Contact
- Christopher Brinzey
- Auditors
- PricewaterhouseCoopers LLP
Upcoming Events for OCUL
Q4 2024 Ocular Therapeutix Inc Earnings Release
Similar to OCUL
111
NASDAQ Global Market
ADMA Biologics
NASDAQ Global Market
ANI Pharmaceuticals
NASDAQ Global Market
Aquestive Therapeutics
NASDAQ Global Market
Avadel Pharmaceuticals
NASDAQ Global Market
FAQ
What is the Ocular Therapeutix share price?
As of Today at 22:24 UTC, shares in Ocular Therapeutix are trading at $9.84. This share price information is delayed by 15 minutes.
How has the Ocular Therapeutix share price performed this year?
Shares in Ocular Therapeutix last closed at $9.84 and the price had moved by +230.2% over the past 365 days. In terms of relative price strength the Ocular Therapeutix share price has outperformed the S&P500 Index by +147.38% over the past year.
What are the analyst and broker recommendations for Ocular Therapeutix?
The overall consensus recommendation for Ocular Therapeutix is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Ocular Therapeutix dividend yield?
Ocular Therapeutix does not currently pay a dividend.
Does Ocular Therapeutix pay a dividend?
Ocular Therapeutix does not currently pay a dividend.
When does Ocular Therapeutix next pay dividends?
Ocular Therapeutix does not currently pay a dividend.
How do I buy Ocular Therapeutix shares?
To buy shares in Ocular Therapeutix you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Ocular Therapeutix?
As of the previous close price of $9.84, shares in Ocular Therapeutix had a market capitalisation of $1.53bn.
Where are Ocular Therapeutix shares listed?
Here are the trading details for Ocular Therapeutix:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: OCUL
What kind of share is Ocular Therapeutix?
Based on an overall assessment of its quality, value and momentum Ocular Therapeutix is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Ocular Therapeutix share price forecast for 2024?
The analyst consensus target price for shares in Ocular Therapeutix is $14.88. That is 51.22% above the last closing price of $9.84.
Analysts covering Ocular Therapeutix currently have a consensus Earnings Per Share (EPS) forecast of -$1.17 for the next financial year.
Find out moreWhat is the trend in the Ocular Therapeutix share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Ocular Therapeutix. Over the past six months, its share price has outperformed the S&P500 Index by +5.46%.
As of the last closing price of $9.84, shares in Ocular Therapeutix were trading +38.51% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Ocular Therapeutix PE Ratio?
The Ocular Therapeutix PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $9.84.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Ocular Therapeutix?
Ocular Therapeutix's management team is headed by:
- Charles Warden - NEC
- Antony Mattessich - PRE
- Donald Notman - CFO
- Michael Goldstein - CEX
- Philip Strassburger - GCN
- Merilee Raines - DRC
- Jeffrey Heier - IND
- Seung Suh Hong - IND
- Richard Lindstrom - IND
- Bruce Peacock - IND
- Leslie Williams - IND